Neoplasms, Head and Neck Clinical Trial
— FOCISDOfficial title:
Normalcy of Food Intake in Head and Neck Cancer Patients Receiving (Chemo)Radiotherapy Supported by Swallowing Therapy and Individual Dietary Counselling. (Supportive Care)
- Background:
Oral nutrition appears to be a challenge for patients with head and neck cancer after
radiotherapy. Many patients desire to (their) `normal food intake` and return to oral
nutrition with normal consistency without modifications and diet formulas. Due to the
dysphagia experienced post treatment this seems tremendously difficult. Referral to a
speech-language therapist for swallowing therapy is no standard procedure.
- Study design:
A prospective randomized study in patients with a tumor in Oral cavity, Nasopharynx,
Oropharynx, Hypopharynx or Larynx with stage II-IV (UICC TNM-tumor classification), ≥ 18
years, eligible for primary treatment with (chemo)radiation or adjuvant radiotherapy with
curative intent.
- Intervention:
Individually tailored swallowing therapy by an experienced speech-language therapist in
cooperation with individual dietary counselling (by an experienced dietician, `usual care`)
pre-, per- and post treatment (until 6 months after treatment). This might improve `normalcy
of food intake`, quality (no food modifications) and quantity of food intake and besides
decrease the use of tube feeding and/or nutritional supplements. Also patients quality of
life and nutritional status may be influenced positively.
- Study hypothesis:
The purpose of this study is to determine whether combined individual swallowing therapy and
individual dietary counselling in patients with head and neck cancer receiving
(chemo)radiotherapy can improve 'normal food intake'. Food intake without modifications and
tube feeding and/or nutritional supplements.
Status | Completed |
Enrollment | 120 |
Est. completion date | December 2012 |
Est. primary completion date | December 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients with tumor in oral cavity, nasopharynx, hypopharynx or larynx with stage II-IV (UICC TNM-tumor classification) - Eligible for primary curative treatment intentions with (chemo)radiation or adjuvant (chemo)radiotherapy - A signed informed consent Exclusion Criteria: - Historical swallowing problems (neurological or not tumor related) - Unable to comprehend and carry out the swallowing rehabilitation - Unable to answer study questions - Radiation or surgery for head and neck cancer in history. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Country | Name | City | State |
---|---|---|---|
Netherlands | Radboud University Nijmegen Medical Centre | Nijmegen | Gelderland |
Lead Sponsor | Collaborator |
---|---|
Radboud University | Fresenius Kabi Nederland BV, Sorgente BV |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Normalcy of food intake | Increase of "normalcy of food intake" of 10% | within 6 months | No |
Secondary | Quality of life | within 6 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01370876 -
Efficacy and Safety Study of Oxaliplatin/5-FU in Patients With Recurrent or Metastatic Head and Neck Cancer
|
Phase 2 | |
Completed |
NCT03178110 -
Manual Therapy and Use of the Dynasplint for Trismus in Patients With Head and Neck Cancer
|
N/A | |
Terminated |
NCT04128696 -
Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
|
Phase 2/Phase 3 | |
Completed |
NCT00798655 -
Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer
|
Phase 2 | |
Completed |
NCT00387127 -
Lapatinib Versus Placebo Given Concurrently With Cisplatin And Radiotherapy In Patients With Unresected Head And Neck Cancer
|
Phase 2 | |
Recruiting |
NCT06062420 -
Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
|
Phase 2 | |
Active, not recruiting |
NCT04260126 -
Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC
|
Phase 2 | |
Active, not recruiting |
NCT02296684 -
Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Recruiting |
NCT06256588 -
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
|
Phase 3 | |
Completed |
NCT01116336 -
Phase I Chemoprevention Trial With Green Tea Polyphenon E & Erlotinib in Patients With Premalignant Lesions of the Head & Neck
|
Phase 1 | |
Recruiting |
NCT02557048 -
Head and Neck Cancer in Children: A Retrospective Study
|
||
Completed |
NCT03356093 -
Change in Symptom Clusters in HNC Patients
|
N/A | |
Terminated |
NCT02376699 -
Safety Study of SEA-CD40 in Cancer Patients
|
Phase 1 | |
Completed |
NCT00424255 -
Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery
|
Phase 3 | |
Completed |
NCT00725764 -
Phase 2 Study of GSK1363089 (Formerly XL880) in Adults With Squamous Cell Cancer of the Head and Neck
|
Phase 2 | |
Terminated |
NCT04428333 -
Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT02573493 -
Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)
|
Phase 2 |